EUVIMEDEUVIMED entdecken
Crossref

Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID ‐19

Shin Watanabe iD, Yosuke Shimizu iD, Hiroyuki Sato iD, Yukari Uemura, Akihiro Hirakawa iD

Pharmaceutical Statistics · 2026-05 · 25 (3)

DOI: 10.1002/pst.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 10.05.2026. Verfasst von Shin Watanabe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, COVID-19, SARS-CoV-2, Antiviral Agents. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID‐19 pandemic spurred the adoption of platform trials for efficient drug development. These trials evaluated multiple treatments simultaneously but faced challenges due to temporal shifts in patient characteristics, trial conduct, and standard of care. A key concern was the use of nonconcurrent control (NCC) data, which can enhance statistical power but may introduce bias if the effects of temporal shifts are not properly adjusted. In this study, we empirically evaluated temporal shifts in clinical outcomes (i.e., time to recovery through Day 28, clinical status on Day 14, and mortality through Day 28) using real‐world platform trial data from the ACTIV‐1 Immune Modulator trial, accounting for the evolving landscape of SARS‐CoV‐2 variants in the CoV‐Spectrum database. We have investigated the operating characteristics of the existing methods using concurrent control and NCC data based on a resampling‐based simulation study using ACTIV‐1 IM trial data, as well as simulations under hypothetical variant‐driven temporal‐shift scenarios that explicitly modeled changes in circulating SARS‐CoV‐2 variants. Our empirical analyses revealed that assumptions in simulation studies—such as specific patterns of temporal shifts and constant treatment effects over time—might not hold in real‐world settings. Simulation studies further showed that in such complex settings, even adjustment methods for leveraging NCC could introduce an unacceptably large bias. Our findings provided an empirical foundation for improving the integration of NCC data and ensuring reliability and efficiency. Real‐world evidence underscored the need for robust statistical methods that account for the temporal shifts in platform trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentCOVID-19SARS-CoV-2Antiviral AgentsClinical Trials as TopicHumansTreatment OutcomeComputer SimulationTime FactorsResearch Design

Stichwörter der Autor:innen

SARS‐CoV‐2 variantnonconcurrent controlpandemicplatform trialreal‐world datatemporal shift

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
  • Laboratory of Biostatistics, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security, Tokyo, Japan.

ORCID-Profile: Shin Watanabe, Yosuke Shimizu, Hiroyuki Sato, Akihiro Hirakawa

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Watanabe, S., Shimizu, Y., Sato, H., Uemura, Y., & Hirakawa, A. (2026). Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID ‐19. Pharmaceutical Statistics, 25(3). https://doi.org/10.1002/pst.70096

Vancouver

Watanabe S, Shimizu Y, Sato H, Uemura Y, Hirakawa A. Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID ‐19. Pharmaceutical Statistics. 2026;25(3). doi:10.1002/pst.70096

BibTeX
@article{Watanabe2026,
  author = {Watanabe, Shin and Shimizu, Yosuke and Sato, Hiroyuki and Uemura, Yukari and Hirakawa, Akihiro},
  title = {Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID ‐19},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {3},
  doi = {10.1002/pst.70096}
}
Kostenlos starten →